Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

• Status: Completed
• Trial end date: 2005-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biogen
• Collaborator: Elan Pharmaceuticals
• Treatments: Natalizumab

Criteria

Inclusion Criteria:

• Diagnosis of MS, as defined by McDonald et al., criteria # 1-4 (McDonald et al., 2001)

• Between the ages of 18 and 50, inclusive.

• Baseline EDSS score between 0.0 and 5.0, inclusive.

• Have experienced at least one relapse within the 12 months prior to randomization.

• Cranial MRI scan demonstrating lesion(s) consistent with MS.

• Have given written informed consent to participate in the study.

Exclusion Criteria:

• Primary progressive, secondary progressive, or progressive relapsing MS.

• MS relapse has occurred,in the opinion of the investigator, within 50 days prior to randomization and/or the subject has not stabilized from a previous relapse.

• A clinically significant infectious illness within 30 days prior to randomization.

• History of, or abnormal laboratory results indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal and/or other major disease, that in the opinion of the investigator, would preclude the administration of a recombinant humanized antibody immunomodulating agent for 116 weeks.

• History of severe allergic or anaphylactic reactions or known drug hypersensitivity.

• Unable to perform the Timed 25-foot Walk, 9HPT, and PASAT 3.

• Abnormal blood tests performed at the Screening Visit.